These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis. Sly N; Gaspar K Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289 [TBL] [Abstract][Full Text] [Related]
8. Midostaurin: First Global Approval. Kim ES Drugs; 2017 Jul; 77(11):1251-1259. PubMed ID: 28612232 [TBL] [Abstract][Full Text] [Related]
9. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Stone RM; Manley PW; Larson RA; Capdeville R Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059 [TBL] [Abstract][Full Text] [Related]
10. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report. Tollkuci E J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838 [TBL] [Abstract][Full Text] [Related]
11. Midostaurin + Chemo Ups AML Survival. Cancer Discov; 2016 Feb; 6(2):OF2. PubMed ID: 26739883 [TBL] [Abstract][Full Text] [Related]
12. Midostaurin for the treatment of acute myeloid leukemia. Patnaik MM Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444 [TBL] [Abstract][Full Text] [Related]
13. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192 [TBL] [Abstract][Full Text] [Related]
14. New Approvals in Cancer Treatment. Aschenbrenner DS Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749878 [No Abstract] [Full Text] [Related]
15. Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis. Galinsky I; Coleman M; Fechter L Clin J Oncol Nurs; 2019 Dec; 23(6):599-608. PubMed ID: 31730602 [TBL] [Abstract][Full Text] [Related]
16. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. Tvedt TH; Nepstad I; Bruserud Ø Expert Opin Investig Drugs; 2017 Mar; 26(3):343-355. PubMed ID: 28001095 [TBL] [Abstract][Full Text] [Related]
17. Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies Manley PW; Weisberg E; Sattler M; Griffin JD Biochemistry; 2018 Feb; 57(5):477-478. PubMed ID: 29188995 [No Abstract] [Full Text] [Related]
18. Midostaurin in FLT3-mutated acute myeloid leukaemia. Das M Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736 [No Abstract] [Full Text] [Related]
19. Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin. Dotson J; Elhamdani A; Petryna E; Jamil MO; Alsharedi M Int J Hematol; 2019 Mar; 109(3):351-355. PubMed ID: 30506467 [TBL] [Abstract][Full Text] [Related]
20. [What is recommended in the treatment of acute myeloid leukemia?]. Thol F Internist (Berl); 2019 Dec; 60(12):1240-1250. PubMed ID: 31690995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]